Inovio announces u.s. fda breakthrough therapy designation granted for ino-3107 for the treatment of recurrent respiratory papillomatosis

• designation based on clinical evidence indicating ino-3107 may demonstrate substantial improvement over existing therapies • first breakthrough therapy designation for an inovio dna medicine candidate plymouth meeting, pa. , sept. 7, 2023 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that the u.s. food and drug administration (fda) has granted breakthrough therapy designation for ino-3107 as a potential treatment for patients with recurrent respiratory papillomatosis (rrp).
INO Ratings Summary
INO Quant Ranking